Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the common sleeping disorder.
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
US FDA says Lilly’s weight-loss drug shortage is resolved
The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly’s (LLY.N) blockbuster weight loss and diabetes drugs following a re-evaluation of their supply by the agency.
FDA says Lilly weight loss drug shortage is over after taking a second look
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound — is over.
Eli Lilly to test weight loss drug Zepbound to treat addiction
Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late-stage clinical trial findings reported Friday.
Novo Nordisk Shares Drop 27% After Obesity Drug Trial Fails to Meet Expectations
Novo Nordisk A/S’s shares plummeted by 27% after its obesity treatment failed to meet expectations in a key trial. The drug helped patients lose weight, but the results fell short of the predicted target.
Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value. The lower-than-expected weight loss from the drug candidate deals a blow to the Danish company’s ambitions for a successor to its Wegovy weight-loss drug that is more powerful than Eli Lilly’s rival Zepbound,
FDA approves weight-loss drug Zepbound to treat sleep apnea
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...
In weight loss battle, Novo and Lilly face growing offensive from licensed copies
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...
Bloomberg L.P. on MSN3d
Lilly’s US Weight-Loss Drug Shortage Ends, Curtailing Copies
Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which ...
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
FDA approves weight-loss drug to treat sleep apnea
The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the ...
health.wusf.usf.edu19h
FDA approves weight loss drug Zepbound to treat obstructive sleep apnea
The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.